Phase II Study of High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis.

Trial Profile

Phase II Study of High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis.

Suspended
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2010

At a glance

  • Drugs Cyclophosphamide (Primary) ; Glatiramer acetate (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Nov 2010 Additional lead trial investigators (Justin McArthur, Daniel Harrison) added as reported by ClinicalTrials.gov record.
    • 08 Nov 2010 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.
    • 24 Mar 2010 Planned initiation date changed from 1 Sep 2009 to 1 Sep 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top